

측두골을 침범한 다발성 골수종 1예

전북대학교 의과대학 이비인후-두경부외과학교실

최승철 · 이재근 · 윤용주

A Case of Multiple Myeloma Involving Temporal Bone

Seung Choul Choi, MD, Jae Keun Lee, MD and Yong Joo Yoon, MD

Department of Otolaryngology-Head and Neck Surgery, School of Medicine,
Chunbuk National University, Jeonju, Korea

—ABSTRACT—

Multiple myeloma (MM) is a systemic manifestation of plasma cell tumor. MM is a relatively well known disease, but the involvement of temporal bone is very rare. In 1979, Lavin first reported the involvement of temporal bone in MM. Symptoms of MM with involvement of temporal bone include hearing loss, tinnitus, dizziness, facial paralysis, and otalgia. The diagnosis of MM may be considered in the presence of a temporal bone mass. Recently, we experienced a case with tinnitus, hearing impairment, and temporal bone mass. The case was later confirmed to be a MM after a pathologic review and a systemic evaluation. We report this rare case with literature reviews. (J Clinical Otolaryngol 2004;15:299-302)

KEY WORDS : Multiple myeloma · Temporal bone · Tinnitus.

서론

Lavin³⁾

1846 Darlympic Bence - Jones's¹⁾
, Willis²⁾가

가

증례

10%

, 1979

54

1

: 2004 9 23

: 2004 11 23

: , 561 - 712

634 - 18

: (063) 250 - 1980 · : (063) 250 - 1986

E - mail : iceboy44@freechal.com

가

70 dB, 15 dB




Fig. 1. The axial CT scan of temporal bone. CT scan shows a huge soft tissue density in the mastoid cavity and bony destructive lesion of mastoid.




Fig. 2. The contrast-enhanced T1-weighted MRI. The T1-weighted MRI image with gadolinium-DPTA shows homogeneously enhanced mass on temporal area.




Fig. 3. The lesion is composed of a dense cellular infiltrate, mainly atypical plasma cells (H & E, $\times 400$).

가 (Fig. 1).
T1
(Fig. 2), T2

6,400/mm³,
145,000/mm³ 9.3
g/dl
4.6 mg/L, 10.1 g/dL,
4.4 5.7 g/dL /
0.8 IgG가 2170 mg/dL
가 , IgA, IgM
M -
Bence - Jones
90%

IgG (Fig. 3).
Vincristin(0.4 mg) adriamycin(13
mg) 4 , dexamethasone(28 mg) 5
6
1 가

301

- 2002;45:1014-7.
- 8) Kim TY, Heo DS, Bang YJ. *Combination chemotherapy with vincristine, melphalan and prednisone for multiple myeloma. The Korean J Int Med* 1993;45:1-11.
- 9) Kyle RA. *Newer approaches to the therapy of multiple myeloma. Blood* 1990;76:1678-9.
- 10) Alexanian R, Dimopoulos M. *The treatment of multiple myeloma. N Engl J Med* 1994;330:484-9.
- 11) Batsakis JG, Fries GT, Goldman RT. *Upper respiratory tract plasmacytoma. Arch Otolaryngol* 1979;79:613-8.
- 12) Quinodoz D, Dulguerov P, Kurt AM, Ruefenacht D, Abele R, Allal AS, et al. *Multiple myeloma presenting with external ear canal mass. J Laryngol Otol* 1998;112:469-71.
- 13) Salmon SE, Haut A, Bonnet JD, Amare M, Weick JK, Durie BG, et al. *Alternating combination chemotherapy and levamisole improves survival in multiple myeloma: A Southwest Oncology Group Study. J Clin Oncol* 1983;1:453-61.
- 14) Oken MM. *Standard treatment of multiple myeloma Mayo. Clin Proc* 1996;69:781-6.
- 15) Bergsagel DE. *Is aggressive chemotherapy more effective in the treatment of plasma cell myeloma. Eur J Cancer Clin Oncol* 1989;25:159-61.
- 16) Shone GR. *Facial palsy due to myeloma of the temporal bone. J Laryngol Otol* 1985;99:907-8.
- 17) Chevalier X, Wrona NN, Larget-Piet B. *Vestibular syndrome in multiple myeloma: Role of magnetic resonance imaging. Clin Rheumatol* 1992;11:405-7.